The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC).
Y. Chen
No relevant relationships to disclose
J. Moon
No relevant relationships to disclose
K. J. Pandya
No relevant relationships to disclose
K. Kelly
No relevant relationships to disclose
L. E. Gaspar
No relevant relationships to disclose
D. Lau
No relevant relationships to disclose
F. R. Hirsch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; OSI Pharmaceuticals; Roche
D. R. Gandara
Consultant or Advisory Role - Bristol-Myers Squibb; ImClone Systems; Sanofi